What is the recommended treatment for fibrosing nonspecific interstitial pneumonia (NSIP)?

Treatment of Fibrosing Nonspecific Interstitial Pneumonia (NSIP)

For fibrosing NSIP, initiate corticosteroid therapy with prednisone at 0.5 mg/kg lean body weight daily for 4 weeks, then taper to 0.25 mg/kg daily for 8 weeks, followed by maintenance at 0.125 mg/kg daily, and add azathioprine (2-3 mg/kg/day up to 150 mg) or cyclophosphamide (2 mg/kg/day up to 150 mg) as combination therapy for at least 6 months before assessing response. 1, 2

Critical Distinction: NSIP vs UIP/IPF

Before initiating treatment, confirm the diagnosis of NSIP rather than UIP/IPF, as corticosteroids are contraindicated in UIP/IPF and may cause harm. 2, 3

Key diagnostic features of NSIP:

• Bilateral symmetric ground-glass opacities with subpleural sparing on HRCT 2, 3
• Temporally uniform inflammation or fibrosis on biopsy (not patchy) 2, 3
• Absence or minimal honeycombing 3, 4
• Preserved alveolar architecture histologically 5

Contrasting UIP/IPF features:

• Subpleural and basal predominant honeycombing with heterogeneous distribution 3
• Fibroblastic foci and architectural distortion 2

First-Line Treatment Protocol

Initial Corticosteroid Regimen

Start treatment at first identification of clinical or physiological impairment: 1, 3

• Weeks 1-4: Prednisone 0.5 mg/kg lean body weight daily 1
• Weeks 5-12: Prednisone 0.25 mg/kg lean body weight daily 1
• Week 13 onward: Prednisone 0.125 mg/kg ideal body weight daily or 0.25 mg/kg every other day 1

Add Immunosuppressive Agent

Initiate simultaneously with corticosteroids: 1

Option 1: Azathioprine (preferred for most patients)

• Start at 25-50 mg/day orally 1
• Increase by 25 mg increments every 7-14 days 1
• Target dose: 2-3 mg/kg lean body weight/day (maximum 150 mg/day) 1

Option 2: Cyclophosphamide (for more aggressive disease)

• Start at 25-50 mg/day orally 1
• Increase by 25 mg increments every 7-14 days 1
• Target dose: 2 mg/kg lean body weight/day (maximum 150 mg/day) 1
• Superior outcomes demonstrated in fibrosing NSIP: 8 of 12 patients improved after 1 year versus 4 of 27 IPF patients 6

Treatment Response Assessment

At 6 Months

Perform repeat pulmonary function tests, HRCT, and symptom assessment: 1

If worse:

• Stop current therapy or switch cytotoxic agent 1
• Consider alternative therapy or lung transplantation evaluation 1

If stable or improved:

• Continue combination therapy at same doses 1

At 12 Months

Reassess with same parameters: 1

If worse:

• Stop therapy 1
• Consider alternative therapy or lung transplantation 1

If stable or improved:

• Continue combination therapy 1

Beyond 18 Months

Continue monitoring and adjust based on disease trajectory. 1

Phenotype-Specific Considerations

Inflammatory NSIP (Better Prognosis)

Characterized by: 4

• Prominent lymphocytic inflammation on BAL 4
• Mixed NSIP/organizing pneumonia pattern on HRCT 4
• Better response to corticosteroids and immunosuppression 4

Highly Fibrotic NSIP (Guarded Prognosis)

Characterized by: 4

• Prominent reticular changes and traction bronchiectasis on HRCT 4
• High fibrotic background on biopsy 4
• No lymphocytosis on BAL 4
• Less responsive to immunosuppression 4
• Risk of evolution toward progressive pulmonary fibrosis 4

Progressive Fibrosing NSIP

If NSIP progresses despite standard immunosuppressive therapy (defined as worsening fibrosis on HRCT, declining FVC, or worsening symptoms), consider nintedanib. 1

The 2022 ATS/ERS/JRS/ALAT guidelines suggest nintedanib for progressive pulmonary fibrosis after failed standard management (conditional recommendation, low-quality evidence). 1

Nintedanib dosing and monitoring:

• Standard dose per FDA approval for progressive fibrosing ILD 1
• Expect increased gastrointestinal adverse effects: diarrhea (2.8×), nausea (3.1×), vomiting (3.6×), abdominal pain (4.2×) 1
• Monitor liver enzymes: elevated AST (3.2×) and ALT (3.6×) 1
• Dose reduction required in 7.9 times more patients versus placebo 1

Pirfenidone is NOT recommended for fibrosing NSIP due to insufficient evidence (38% of guideline committee abstained from voting, citing inadequate data). 1

Supportive Care Measures

Throughout treatment, implement: 2, 4

• Pulmonary rehabilitation for all symptomatic patients 2
• Oxygen therapy for hypoxemia 2
• PCP prophylaxis if receiving ≥20 mg methylprednisolone equivalent for ≥4 weeks 2
• Calcium and vitamin D supplementation for long-term steroid use 2
• Proton pump inhibitors for GI prophylaxis 2
• Blood glucose monitoring and treatment per standard guidelines 2
• Bone density testing and bisphosphonates as indicated 2

Prognosis

Fibrosing NSIP carries significantly better prognosis than UIP/IPF: 3, 6

• 15-20% mortality at 5 years with treatment 2, 3
• Median survival substantially longer than IPF (4.1 years) 6
• Majority of patients show improvement or stabilization with combination therapy 2, 6

Critical Pitfalls to Avoid

Do not treat presumed NSIP with corticosteroids without histopathologic confirmation, as misdiagnosed UIP/IPF patients may be harmed by corticosteroid therapy. 2, 3

Do not discontinue therapy before 6 months unless adverse effects occur, as discernible response may not be evident until after 3 months of treatment. 1

Do not use pirfenidone as first-line therapy for fibrosing NSIP—reserve antifibrotics only for progressive disease despite immunosuppression. 1